Background <p>Challenges to developing immunotherapies for acute myeloid leukemia (AML) include the identification of suitable target antigens due to on-target-off-leukemia toxicity. CD70, expressed on AML bulk and leukemic stem cells with limited expression on healthy cells, has emerged as a promising target.</p> Methods <p>This study evaluated CD70 as a target for NK-cell-based immunotherapy using a sugar-engineered antibody (PF-08046040, SEA-CD70). CD70…
TNF-{alpha} and IFN-{gamma} differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity
Journal for ImmunoTherapy of Cancer | | Sponheimer, M., White, K., Ulrich, M., Kazerani, M., Maiser, A., Tyborski, E. T., Rappa, G. P., Richter, D., Briem, E., Hänel, G., Philipp, N., Nixdorf, D., Rohrbacher, L., Marcinek, A., Linder, A., Kuhl, N., Piseddu, I., Straub, T., Harz, H., Wichmann, C., Maenner, D., Rudelius, M., Hornung, V., Leonhardt, H., Van Elssen, C. H. M. J., Abdelhamed, S., Diolaiti, D., Bücklein, V., Subklewe, M.
Topics: blood-cancer, immunotherapy, chemotherapy, research
Read the full article at Journal for ImmunoTherapy of Cancer